The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome

Scharf, Christina; Liebchen, Uwe; Paal, Michael; Taubert, Max; Vogeser, Michael; Irlbeck, Michael; Zoller, Michael; Schroeder, Ines

doi:10.1186/s40560-020-00504-w

Journal of Intensive Care

Table 2 Statistical analysis of the patient characteristics with one-way analysis of variance and post hoc Tukey test

From: The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome

	One-way ANOVA (p)	Post hoc 1–2 (p)	Post hoc 1–3 (p)	Post hoc 2–3 (p)	95% CI 1–2	95% CI 1–3	95% CI 2–3
Baseline parameters
IL 6 d1	0.286	0.999	0.374	0.304	− 254–263	− 458–129	− 443–105
CRP d1	0.805	0.861	0.813	0.985	− 8.08–5.19	− 9.47–5.62	− 7.52–6.54
Creatinine d1	< 0.001	0.702	< 0.001	< 0.001	− 0.7–0.4	− 1.7 to − 0.5	− 1.5 to − 0.3
Urea d1	0.001	0.260	0.001	0.021	− 35–7	− 64 to − 16	− 48 to − 3
CLCR d1	< 0.001	0.002	< 0.001	0.007	17–88	61–138	11–83
RRT d1	0.066	0.832	0.066	0.146	− 0.3–0.2	− 0.6–0.02	− 0.5–0.06
Bilirubin d1	0.499	0.947	0.677	0.475	− 1.5–1.9	− 2.6–1.2	− 2.6–0.9
ALT d1	0.723	0.781	0.754	0.988	− 174–306	− 196–361	− 249–281
AST d1	0.728	0.938	0.900	0.706	− 308–230	− 250–361	− 191–379
GGT d1	0.283	0.931	0.482	0.261	− 108–145	− 213–75	− 222–46
APACHE II d1	0.026	0.989	0.061	0.03	− 5.0–5.6	− 11.8–0.2	− 11.7 to − 0.5
SOFA d1	0.133	0.123	0.338	0.703	− 4.3–1.1	− 5.7–0.5	− 3.8–1.9
Age	0.010	0.204	0.007	0.183	− 17.1–2.8	− 26.3 to − 3.6	− 18.4–2.7
BMI	0.845	1.00	0.874	1.00	− 11.0–11.0	− 10.0–15.1	− 9.1–14.3
Sex	0.78	0.82	0.806	0.994	− 0.5–0.3	− 0.6–0.3	− 0.4–0.4
Delta parameters
ΔIL-6 (d1–d3)	0.236	0.959	0.255	0.319	− 291–231	− 494–100	− 444–109
ΔCRP (d1–d3)	0.015	0.033	0.026	0.903	− 11.2 to − 0.4	− 12.9 to − 0.67	− 6.7–4.7
ΔCreatinine (d1–d5)	0.253	0.900	0.236	0.37	− 0.4–0.6	− 0.2–1.1	− 0.3–1.0
ΔUrea (d1–d5)	0.327	0.79	0.657	0.298	− 34–20	− 21–45	− 12–50
ΔCLCR (d1–d5)	0.419	0.398	0.891	0.763	− 22–73	− 45–66	− 67–37
ΔBilirubin (d1–d5)	0.946	0.957	1.00	0.961	− 1.3–1.7	− 1.7–1.7	− 1.7–1.4
ΔALT (d1–d5)	0.526	0.632	0.553	0.978	− 174–306	− 196–361	− 249–281
ΔAST (d1–d5)	0.781	0.999	0.841	0.782	− 242–232	− 206–330	− 175–310
ΔGGT (d1–d5)	0.765	0.951	0.750	0.869	− 190–244	− 171–319	− 175–268
ΔAPACHE II (d1–d5)	0.227	0.358	0.231	0.887	− 1.3–4.7	− 1.0–5.6	− 2.4–3.6
ΔSOFA (d1–d5)	0.215	0.197	0.766	0.597	− 1.7–10.3	− 4.8–8.6	− 10.3–1.7
Neurological disorder d5	0.43	0.473	0.518	0.997	− 0.6–0.2	− 0.6–0.2	− 0.4–0.4
In-hospital mortality	0.002	0.728	0.001	0.017	− 0.2 – 0.4	− 0.7 to − 0.06	− 0.8 to − 0.2
Estimated mortality	0.123	0.996	0.198	0.135	− 0.1 – 0.1	− 0.3–0.05	− 0.3–0.03

ANOVA analysis of variance, CI confidence interval, IL-6 interleukin-6, CRP C-reactive protein, ALT serum alanine aminotransferase, AST serum aspartate aminotransferase, GGT glutamine glutamyl transferase, CLCR creatinine clearance, RRT renal replacement therapy, d day, BMI body mass index

Back to article page

ISSN: 2052-0492

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com